the percentages are just for price risking - how much do discount the value that product brings to the share price. They have done this accurately in their guidance.
I agree with BP on most of this stuff (except possibly the price target). I think success at the type A meeting is likely to be inhibited by the FDA's clear need for an MSC RCT, we should see scenario 2 or 3 from their report.
Covid breaks the ice for approval on the other products because it is a full RCT and the FDA wants therapies to be approved so they have tools to fight the pandemic. Q4 and Q1 2021 there's going to be a few new therapies for covid approved, I think. Ours will be just one, but it's big for MSB and future products!
if the price tanks after the type A meeting I'll buy a trading parcel.
MSB Price at posting:
$3.41 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)